Monopar Sale Purchase Of Stock vs Change To Liabilities Analysis
MNPR Stock | USD 25.34 3.29 14.92% |
Monopar Therapeutics financial indicator trend analysis is infinitely more than just investigating Monopar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monopar Therapeutics is a good investment. Please check the relationship between Monopar Therapeutics Sale Purchase Of Stock and its Change To Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.
Sale Purchase Of Stock vs Change To Liabilities
Sale Purchase Of Stock vs Change To Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monopar Therapeutics Sale Purchase Of Stock account and Change To Liabilities. At this time, the significance of the direction appears to have no relationship.
The correlation between Monopar Therapeutics' Sale Purchase Of Stock and Change To Liabilities is 0.05. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Change To Liabilities in the same time period over historical financial statements of Monopar Therapeutics, assuming nothing else is changed. The correlation between historical values of Monopar Therapeutics' Sale Purchase Of Stock and Change To Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Monopar Therapeutics are associated (or correlated) with its Change To Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Liabilities has no effect on the direction of Sale Purchase Of Stock i.e., Monopar Therapeutics' Sale Purchase Of Stock and Change To Liabilities go up and down completely randomly.
Correlation Coefficient | 0.05 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Sale Purchase Of Stock
Change To Liabilities
Most indicators from Monopar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.As of 12/26/2024, Selling General Administrative is likely to drop to about 2.2 M. In addition to that, Tax Provision is likely to drop to about (67.7 K)
2021 | 2022 | 2023 | 2024 (projected) | |
Total Operating Expenses | 9.1M | 10.5M | 8.8M | 7.5M |
Research Development | 6.5M | 7.6M | 5.6M | 5.3M |
Monopar Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Monopar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Monopar Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.4M | 16.9M | 20.5M | 13.2M | 7.3M | 11.5M | |
Total Current Liabilities | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Total Stockholder Equity | 12.6M | 15.7M | 18.9M | 10.1M | 5.6M | 10.4M | |
Net Tangible Assets | 6.9M | 12.6M | 15.7M | 18.9M | 21.8M | 10.9M | |
Retained Earnings | (25.9M) | (32.2M) | (41.3M) | (51.8M) | (60.2M) | (57.2M) | |
Accounts Payable | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Cash | 13.2M | 16.7M | 20.3M | 8.2M | 7.3M | 10.5M | |
Total Liab | 724.2K | 1.2M | 1.6M | 3.1M | 1.8M | 1.1M | |
Total Current Assets | 13.2M | 16.8M | 20.5M | 13.2M | 7.3M | 11.2M | |
Other Current Liab | 724.2K | 1.2M | 1.6M | (48.6K) | 1.8B | 1.8B | |
Net Debt | (13.2M) | (16.7M) | (20.3M) | (8.2M) | (7.3M) | (7.6M) | |
Non Current Assets Total | 0.0 | 122.4K | 68.9K | 61.2K | 12.6K | 12.0K | |
Cash And Short Term Investments | 13.2M | 16.7M | 20.3M | 13.1M | 7.3M | 12.2M | |
Common Stock Shares Outstanding | 10.6M | 11.0M | 12.5M | 12.7M | 14.5M | 12.7M | |
Liabilities And Stockholders Equity | 13.4M | 16.9M | 20.5M | 13.2M | 7.3M | 12.6M | |
Capital Surpluse | 28.0M | 28.6M | 38.5M | 47.9M | 55.1M | 32.5M | |
Other Current Assets | 5.4K | 62.7K | 217.7K | 46.0K | 66.4K | 99.5K | |
Other Stockholder Equity | 38.5M | 47.9M | 60.2M | 61.9M | 65.8M | 46.1M | |
Net Invested Capital | 12.6M | 15.7M | 18.9M | 10.1M | 5.6M | 5.3M | |
Net Working Capital | 12.5M | 15.6M | 18.9M | 10.0M | 5.6M | 5.3M | |
Common Stock | 10.6K | 11.5K | 12.6K | 12.9K | 14.9K | 12.7K | |
Accumulated Other Comprehensive Income | (11.0K) | (7.9K) | (3.2K) | 8.9K | (14.1K) | (13.4K) | |
Capital Stock | 10.6K | 11.5K | 12.6K | 12.9K | 14.9K | 13.2K |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
0.84 | DTIL | Precision BioSciences | PairCorr |
0.82 | ME | 23Andme Holding | PairCorr |
0.79 | VALN | Valneva SE ADR | PairCorr |
0.77 | VINC | Vincerx Pharma | PairCorr |
0.75 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.